Why You Need Mass Spec for Veterinary Drug Residue and Antibiotic Analysis

May 25, 2018 | Blogs, Food / Beverage | 0 comments

As hospitals struggle with increasingly hard-to-treat antimicrobial resistance (ARM) bacterial infections, related deaths now exceed 700,000 per year globally and are predicted to reach 10 million per year by 2050. There’s no denying that these statistics are both shocking and concerning, as existing antibiotics are increasingly losing their effectiveness.

While researchers work relentlessly to discover new classes of powerful antibiotics that could someday help to address a looming public health crisis, measures are being taken to restrict the impact of drug-resistant infections. AMR occurs naturally over time and is a complex issue with a multitude of factors to consider when it comes to quantifying causes and managing prevention. However, antibiotic resistance is accelerated by the misuse and overuse of antibiotics, and the link between animal ingestion of antibiotics and increasing resistance in humans is widely acknowledged.

Preventing Drug Residues Hitchhiking into the Food Chain
Veterinary drug residues are making their way into the food chain, and human consumption of meat, fish, and crops is contributing to ARM, as well as other health epidemics such as hypersensitivity reactions and carcinogenicity. The use of antibiotics for livestock greatly exceeds the use for humans, and it is estimated that animal ingestion of antibiotics accounts for approximately 70-80 percent of total consumption worldwide. This is having a direct impact on human antibiotic intake.

Fortunately, there is a higher awareness of potential risks surrounding the (improper) use of veterinary drugs, and many countries have enforced legislation to restrict the usage of these substances. Agriculture will always include a level of necessary use for good animal welfare or to prevent crop failure, but the intention is to reduce veterinary drug residue levels in food products.

Multiclass Veterinary Drug Residue and Antibiotic Analysis
Detecting trace quantities of veterinary drug residues can be challenging for labs because they are complex, containing actives from a variety of chemical classes, such as antibiotics, antiparasitics, and non-steroidal anti-inflammatory drugs. While there are several analytical approaches available, few come close to mass spectrometry in delivering a fast and highly selective routine screening method.

High-resolution accurate mass spec technology from SCIEX is proven to identify and quantify very low levels of multiclass antibiotics and hormone residues across a comprehensive range of food samples:

  • X500R QTOF with SWATH® Acquisition analyses data faster
  • Verified spectral library with hundreds of antibiotics
  • Accurately profile the composition of samples
  • Rapid glycan heterogeneity identification
  • Highly selective MRMHR detects trace levels
  • Maximize uptime and robustness with SCIEX Turbo V™ source
  • Tackle difficult matrices with co-eluting matrix compounds

SCIEX combines best-in-class mass spec hardware, software and support services to bring you an extensive solution for faster and simpler multi-residue detection. If you want to simplify your veterinary drug residue and antibiotic analysis workflows with an accurate method that analyzes low levels of analytes within complex matrices, look no further than the cutting edge high-resolution accurate mass spec solutions from SCIEX.Access a range of informative videos, webinars, tech sheets and other useful resources >

 

 

PFAS testing: 2024 in review and what to expect for 2025

For as long as PFAS persist in the environment, there is no doubt they will persist in our conversations as environmental scientists. Globally, PFAS contamination has been detected in water supplies, soil and even in the blood of people and wildlife. Different countries are at various stages of addressing PFAS contamination and many governments have set regulatory limits and are working on assessing the extent of contamination, cleaning up affected sites and researching safer alternatives.

Inside the box: Acoustic ejection mass spectrometry for drug discovery

On average, it takes 10-15 years and 1-2 billion dollars to approve a new pharmaceutical for clinical use. Since approximately 90% of new drug candidates fail in clinical development, the ability to make early, informed and accurate decisions on the safety and efficacy of new hits and leads is key to increasing the chances of success.

Unveiling the power of ZT Scan DIA: Insights from Ludwig Sinn’s presentation at World HUPO Congress 2024

In a recent presentation at the World HUPO Congress 2024, Ludwig Sinn from the Ralser lab shared exciting advancements in proteomics research, focusing on the innovative ZT Scan DIA acquisition modes developed in collaboration with SCIEX. Let us explore the key highlights and benefits of this innovative technology.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial